Exelixis traded at $55.47 this Wednesday July 15th, decreasing $0.30 or 0.54 percent since the previous trading session. Looking back, over the last four weeks, Exelixis lost 6.47 percent. Over the last 12 months, its price rose by 23.79 percent. Looking ahead, we forecast Exelixis to be priced at 55.32 by the end of this quarter and at 51.92 in one year, according to Trading Economics global macro models projections and analysts expectations.
Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development and commercialization of medicines to treat cancers. Its platform also provides therapies to cancer patients with additional treatment options. The Company's cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. The products derived from cabozantinib are CABOMETYX tablets for renal cell carcinoma (RCC) and COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). Its other two product candidates are COTELLIC (cobimetinib), is an inhibitor of MEK with multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO (esaxerenone), is an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) for the treatment of hypertension. Its phase I b clinical trial programs include XL092, STELLAR-001 and STELLAR-002.